Ocular safety profile of novel oral antithrombotics explored
(HealthDay)—Prasugrel carries no increased ocular risk compared with clopidogrel, and dabigatran and rivaroxaban may reduce risk compared with warfarin, according to a study published online Dec. 14 in JAMA Ophthalmology.
Dec 14, 2017
0
5